Literature DB >> 3391513

Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: comparison with the effects on portal pressure.

J Bosch1, J M Bordas, R Mastai, D Kravetz, M Navasa, J Chesta, M P Pizcueta, J C García-Pagán, J Rodés.   

Abstract

The present study investigated to what extent measurements of wedged and free hepatic venous pressures adequately reflect the effects of vasopressin at the esophageal varices in patients with cirrhosis. Eleven patients undergoing therapeutic sclerotherapy were studied by measuring wedged hepatic venous pressure, intravariceal pressure, free hepatic venous pressure, superior vena cava pressure and the intravascular pressure gradients wedged hepatic venous pressure-free hepatic venous pressure and intravariceal pressure-superior vena cava pressure, prior to and after vasopressin injection (1 IU, iv). Vasopressin caused a significant reduction in intravariceal pressure (from 22.5 +/- 9.4 to 19.2 +/- 8.4 mm Hg, p less than 0.001). Measurement of wedged hepatic venous pressure and free hepatic venous pressure closely reflected the reduction in variceal pressure. Thus, wedged hepatic venous pressure decreased by 16 +/- 11%, which is close to the 14 +/- 7% change in intravariceal pressure, and the 23 +/- 12% fall in the pressure gradient wedged hepatic venous pressure-free hepatic venous pressure was mirrored by the 26 +/- 10% change in intravariceal pressure-superior vena cava pressure. These pressure gradients decreased more than the absolute pressures (intravariceal pressure and wedged hepatic venous pressure) due to concomitant increases in superior vena cava pressure (1.9 +/- 1.9 mm Hg) and free hepatic venous pressure (0.6 +/- 1.9 mm Hg).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3391513     DOI: 10.1002/hep.1840080427

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  6 in total

1.  Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis.

Authors:  S Sugano; T Kawafune; T Okajima; K Ishii; M Watanabe; N Takamura
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

2.  Portal and systemic haemodynamic response to acute and chronic administration of low and high dose isosorbide-5-mononitrate in patients with cirrhosis.

Authors:  A L Jones; I H Bangash; J Walker; K J Simpson; N D Finlayson; P C Hayes
Journal:  Gut       Date:  1995-01       Impact factor: 23.059

Review 3.  The use of vasopressin in the treatment of upper gastrointestinal haemorrhage.

Authors:  D L Stump; T C Hardin
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

4.  Chronic splanchnic hemodynamic effects of low-dose transdermal nitroglycerin versus low-dose transdermal nitroglycerin plus spironolactone in patients with cirrhosis.

Authors:  S Sugano; T Suzuki; M Nishio; H Makino; T Okajima
Journal:  Dig Dis Sci       Date:  1997-03       Impact factor: 3.199

Review 5.  Variceal bleeding : pharmacological treatment and prophylactic strategies.

Authors:  Cándid Villanueva; Joaquim Balanzó
Journal:  Drugs       Date:  2008       Impact factor: 9.546

6.  Quantitative modeling of the physiology of ascites in portal hypertension.

Authors:  David G Levitt; Michael D Levitt
Journal:  BMC Gastroenterol       Date:  2012-03-27       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.